Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Health care stocks were mixed in Wednesday afternoon trading, with the NYSE Health Care Index fractionally higher and the Health Care Select Sector SPDR Fund (XLV) slightly lower. The iShares Biotechn
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise
NeuroBo Pharmaceuticals (NRBO) said Wednesday the first patient has been dosed in part 1 of its two-part early-stage trial of DA-1726 for the treatment of obesity. The company said part 1 of the study
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascend
NeuroBo Pharmaceuticals Files For Mixed Shelf Offering Of Up To $150M
https://www.sec.gov/Archives/edgar/data/1638287/000155837024005018/tmb-20240412xs3.htm
NeuroBo Pharmaceuticals GAAP EPS of -$2.46
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down
NeuroBo Pharmaceuticals (NRBO) said Wednesday it received the go-ahead to continue its mid-stage clinical trial of DA-1241 without modification, a treatment for metabolic dysfunction-associated steato
NeuroBo's Phase 2a Trial of DA-124 Proceeds After Safety Review
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NASDAQ:NRBO), a biotech firm specializing in cardiometabolic diseases, announced today that its Phase 2a clinical trial of DA-1241 will continue without changes following a favorable safety review.
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
NeuroBo Pharmaceuticals Announces Key Leadership Appointment
NeuroBo Pharmaceuticals Appoints Marshall H. Woodworth As Chief Financial Officer, Effective March 1, 2024
On March 1, 2024, the Board of Directors (the "Board") of NeuroBo Pharmaceuticals, Inc. (the "Company") appointed Mr. Marshall H. Woodworth, age 66, as the Company's Chief Financial Officer, Principal
NeuroBo Stock Jumps 14% on Weight-loss Drug Update
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersEnveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. Societal CDMO (NASDAQ:SCTL) shares moved upwa
NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 12, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced
Biosig Technologies, NeueHealth Among Healthcare Movers
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.97%
US Equity Markets Close Higher Thursday Following Jobless Claims Data
US equity markets ended stronger Thursday as investors weighed higher-than-expected jobless claims data. * Initial jobless claims rose to 224,000 in the week ended Jan. 27 from an upwardly revised 215
NeuroBo Pharmaceuticals NRBO IND Cleared; Kiora Pharmaceuticals KPRX Deal
Trending Stocks Today: GRI Bio Shoots up 61.41%
February 1st - US stocks trending in regular trading hours.Gainers: $GRI Bio(GRI.US)$ surges 61.41% to $2.62 with a turnover of $60.29 million. $NeuroBo Pharmaceuticals(NRBO.US)$ shoots up 74.92% to $
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading
Health care stocks were higher Thursday afternoon, with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) up 1%. The iShares Biotechnology ETF (IBB) gained 1.4%.
No Data